炎症性肠病与肠道细菌研究进展

Advance on the relationship between inflammatory bowel disease and intestinal bacteria

炎症性肠病(inflammatory bowel disease,IBD)包括溃疡性结肠炎(ulcerative colitis,UC)和克罗恩病(Crohn's disease,CD).其发病机制至今仍不清楚,可能的病因包括由基因决定的宿主易感性、黏膜免疫和肠道微生态环境三者的相互作用.近年来随着微生态学的发展,肠道菌群与IBD发病的关系日益受到关注.关于肠道病原微生物在IBD发病机制及其引起的一系列免疫学、微生态学、病理生理等方面的变化出现了研究和报道,同时微生态制剂在肠道免疫调节、控制炎症反应等方面的优点已有许多动物实验及临床应用证明,其中微生态制剂之一益生菌在IBD应用较普遍,本文就IBD与肠道菌群研究进展及益生菌制剂治疗IBD作一综述.

The pathogenesis of inflammatory bowel disease, including ulcerative colitis and Crohn＇s disease, is still not entirely understood today. The possible etiology includes host genetic sus- ceptibility, mucosal immunity and intestinal microecology as well as their interactions. With the development of mircoecology in recent years, there were increasing interests in the correlation between intestinal bacteria and pathogenesis of IBD. Many studies reported the pathogenesis of enteropathogenic microorganism and a series of immunological, microecological and pathophysiological changes in IBD. At the same time, many animal experiments and clinical ap- plications have proved the predominance of microecological preparation on intestinal tract immunoloregulation, controlling of inflammatory reaction and so on. Probiotics which is one of the microecological preparation has been generally used. This article reviewed the advances on the relationship between inflammatory bowel disease and intestinal bacteria and the use of probiotics in the treatment of IBD.